Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial

IMPORTANCE: The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germli...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Hahnen, Eric, Lederer, Bianca, Hauke, Jan, Loibl, Sibylle, Kröber, Sandra, Schneeweiss, Andreas, Denkert, Carsten, Fasching, Peter A., Blohmer, Jens U., Jackisch, Christian, Paepke, Stefan, Gerber, Bernd, Kümmel, Sherko, Schem, Christian, Neidhardt, Guido, Huober, Jens, Rhiem, Kerstin, Costa, Serban, Altmüller, Janine, Hanusch, Claus, Thiele, Holger, Müller, Volkmar, Nürnberg, Peter, Karn, Thomas, Nekljudova, Valentina, Untch, Michael, von Minckwitz, Gunter, Schmutzler, Rita K.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2017
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5710508/
https://ncbi.nlm.nih.gov/pubmed/28715532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.1007
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars